Sulfamethoxazole in a CAPD Patient

Abstract

Get full access to this article

View all access options for this article.

References

Keane

W.K.

, Everett

E.D.

, Golper

T.A.

Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update.

Perit Dial Int 1993; 13: 14–28.

Pate

I.R.B.

, Welling

P.G.

Clinical pharmacokinetics of cotrimoxazole (trimethoprim-sulfamethoxazole).

Clin Pharmacokinet 1980; 5: 405–23.

Gotloib

, Mines

, Servadio

, Kohan

Delayed excretion of conjugated sulphamethoxazole in uraemia.

Proc Eur Dial Transplant Assoc 1975; 11: 405–10.

Vree

T.B.

, Hekster

Y.A.

, Damsma

J.E.

Renal excretion of sulphamethoxazole and its metabolite N4acetylsulphamethoxazole in kidney function.

Ther Drug Monit 1981; 3: 129–35.

Walker

S.E.

, Paton

T.W.

, Churchill

D.N.

Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD).

Perit Dial Int 1989; 9: 51–5.

Halstenson

C.E.

, Blevins

R.B.

, Salem

N.G.

Trim ethoprim-sulfame thoxaz o I e p harmacokinetics during continuous ambulatory peritoneal dialysis.

Clin Nephrol 1984; 22(5): 239–43.

Bennett

W.M.

, Aronoff

G.R.

, Morrison

Drug prescribing in renal failure: dosing guidelines for adults.

Am J Kidney Dis 1983; 3(3): 155–93.

Singlas

, Colin

J.N.

, Rottembourg

Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis.

Eur J Clin Pharmacol 1982; 21: 409–15.